The Synovial Sarcoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Synovial Sarcoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Synovial Sarcoma Market.
Some of the key takeaways from the Synovial Sarcoma Pipeline Report:
Companies across the globe are diligently working toward developing novel Synovial Sarcoma treatment therapies with a considerable amount of success over the years.
Synovial Sarcoma companies working in the treatment market are OncoTherapy Science, BioAtla, Inc., Takara Bio, C4 Therapeutics, Adaptimmune, Epizyme, Inc., Advenchen Laboratories, Philogen, Nanobiotix, Monopar Therapeutics, Lytix Biopharma, Jazz Pharmaceuticals, Foghorn Therapeutics Inc., and others, are developing therapies for the Synovial Sarcoma treatment
Emerging Synovial Sarcoma therapies such as – OTSA101, CAB-AXL-ADC, NY-ESO-1, CFT – 8634, Afamitresgene autoleucel, Tazemetostat, AL3818, L19 TNF, NBTXR3, GPX-150, LTX-315, Lurbinectedin, FHD-609, and others are expected to have a significant impact on the Synovial Sarcoma market in the coming years.
In May 2023, In order to examine the efficacy and safety of afamitresgene autoleucel in HLA-A*02 eligible and MAGE-A4 positive individuals aged 2 to 21 with advanced malignancies, Adaptimmune will begin a Phase I/II paediatric basket study
In October 2022, The Spanish Agency for Medicines and Health Products (Agencia Espanola de Medicamentos y Productos Sanitarios, AEMPS) has approved a Phase 1b/randomized Phase 2 study comparing the effectiveness of doxorubicin alone versus doxorubicin plus LB-100, the company’s lead clinical compound, for the initial treatment of advanced soft tissue sarcomas (ASTS).
In September 2022, In order to facilitate an investigator-initiated open-label Phase II clinical trial, Immutep Limited is happy to announce that it has executed a Material Transfer Agreement (“Agreement”) with the Maria Skodowska-Curie National Research Institute of Oncology in Warsaw, Poland. Up to 40 patients with select soft tissue sarcoma (STS) will participate in the trial to assess Immutep’s principal product candidate, efti, in combination with pembrolizumab and radiation in the neoadjuvant situation (before to surgery).
In July 2020, the EMA granted Afamitresgene Autoleucel PRIME status for the treatment of Synovial Sarcoma. ADP-A2M4 to treat synovial sarcoma has been given the FDA Regenerative Medicine Advanced Therapy (RMAT) designation, according to an announcement made by Adaptimmune Therapeutics plc in December 2019
Synovial Sarcoma Overview
Soft tissue sarcomas (STS) have a special subtype known as synovial sarcomas (SS), which make up between 5 and 10% of all STS. The clinical appearance and very early age upon diagnosis set synovialsarcoma apart from other STS. Unique genomic features of synovial sarcomas are caused by a pathognomonic t(X;18) chromosomal translocation, which leads to the development of the SS18:the oncogenes SSX.
Get a Free Sample PDF Report to know more about Synovial Sarcoma Pipeline Therapeutic Assessment-
Emerging Synovial Sarcoma Drugs Under Different Phases of Clinical Development Include:
OTSA101: OncoTherapy Science
CAB-AXL-ADC: BioAtla, Inc.
CFT 8634: C4 Therapeutics
FHD 609: Foghorn Therapeutics
NY-ESO-1: Takara Bio
CFT – 8634: C4 Therapeutics
Afamitresgene autoleucel: Adaptimmune
Tazemetostat: Epizyme, Inc.
Route of Administration
Synovial Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Products have been categorized under various Molecule types, such as
Synovial Sarcoma Pipeline Therapeutics Assessment
Synovial Sarcoma Assessment by Product Type
Synovial Sarcoma By Stage and Product Type
Synovial Sarcoma Assessment by Route of Administration
Synovial Sarcoma By Stage and Route of Administration
Synovial Sarcoma Assessment by Molecule Type
Synovial Sarcoma by Stage and Molecule Type
DelveInsight’s Synovial Sarcoma Report covers around 14+ products under different phases of clinical development like-
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Synovial Sarcoma product details are provided in the report. Download the Synovial Sarcoma pipeline report to learn more about the emerging Synovial Sarcoma therapies
Some of the key companies in the Synovial Sarcoma Therapeutics Market include:
Key companies developing therapies for Synovial Sarcoma are – dvenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
Synovial Sarcoma Pipeline Analysis:
The Synovial Sarcoma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Synovial Sarcoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Synovial Sarcoma Treatment.
Synovial Sarcoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Synovial Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Synovial Sarcoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Synovial Sarcoma drugs and therapies
Synovial Sarcoma Pipeline Market Drivers
Increasing Incidence of Synovial Sarcoma, increasing research and development activities for the development of targeted therapies are some of the important factors that are fueling the Synovial Sarcoma Market.
Synovial Sarcoma Pipeline Market Barriers
However, lack of approved therapies, adverse effects associated with the drugs and other factors are creating obstacles in the Synovial Sarcoma Market growth.
Scope of Synovial Sarcoma Pipeline Drug Insight
Key Synovial Sarcoma Companies: OncoTherapy Science, BioAtla, Inc., Takara Bio, C4 Therapeutics, Adaptimmune, Epizyme, Inc., Advenchen Laboratories, Philogen, Nanobiotix, Monopar Therapeutics, Lytix Biopharma, Jazz Pharmaceuticals, Foghorn Therapeutics Inc., and others
Key Synovial Sarcoma Therapies: OTSA101, CAB-AXL-ADC, NY-ESO-1, CFT – 8634, Afamitresgene autoleucel, Tazemetostat, AL3818, L19 TNF, NBTXR3, GPX-150, LTX-315, Lurbinectedin, FHD-609, and others
Synovial Sarcoma Therapeutic Assessment: Synovial Sarcoma current marketed and Synovial Sarcoma emerging therapies
Synovial Sarcoma Market Dynamics: Synovial Sarcoma market drivers and Synovial Sarcoma market barriers
Request for Sample PDF Report for Synovial Sarcoma Pipeline Assessment and clinical trials
Table of Contents
Synovial Sarcoma Report Introduction
Synovial Sarcoma Executive Summary
Synovial Sarcoma Overview
Synovial Sarcoma- Analytical Perspective In-depth Commercial Assessment
Synovial Sarcoma Pipeline Therapeutics
Synovial Sarcoma Late Stage Products (Phase II/III)
Synovial Sarcoma Mid Stage Products (Phase II)
Synovial Sarcoma Early Stage Products (Phase I)
Synovial Sarcoma Preclinical Stage Products
Synovial Sarcoma Therapeutics Assessment
Synovial Sarcoma Inactive Products
Company-University Collaborations (Licensing/Partnering) Analysis
Synovial Sarcoma Key Companies
Synovial Sarcoma Key Products
Synovial Sarcoma Unmet Needs
Synovial Sarcoma Market Drivers and Barriers
Synovial Sarcoma Future Perspectives and Conclusion
Synovial Sarcoma Analyst Views
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Address:27 Drydock Ave S. Jones Blvd #2432
Country: United States